Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Joel H. Rubenstein, Thomas D. Wang, D.K. Turgeon, Tse-Shao Chang, Henry D. Appelman, Bishnu P. Joshi, Richard S. Kwon, David G. Beer, Eric J. Seibel, Juan Zhou, Erik Jan Wamsteker, Yang Jiang, Jing Chen
Publikováno v:
Gut
Improved methods for early cancer detection arising from Barrett’s oesophagus (BE) are still needed. Imaging molecular expression patterns in BE patients can target neoplasia. We demonstrate a multiplexed fluorescence imaging approach to detect pre
Autor:
Jingfei Ma, Asif Rashid, Subramanya Sandesh, Anuj Verma, Jia Sun, Ignacio I. Wistuba, Jason Stafford, Aliya Qayyum, Ken Pin Hwang, Rony Avritscher, Richard L. Ehman, Ahmed Kaseb, Manal M. Hassan, Roberto Carmagnani Pestana, Hesham M. Amin, Dipen M. Maru
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-6 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Currently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherap
Autor:
Alexia Iasonos, Roisin E. O'Cearbhaill, Qin Zhou, Ekaterina Doubrovina, David R. Spriggs, Carol Aghajanian, Sara Kravetz, Richard J. O'Reilly, Paul Sabbatini, Chrisann Kyi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundThis phase I dose escalation trial evaluated the feasibility of production, safety, maximum tolerated dose, and preliminary efficacy of autologous T cells sensitized with peptides encoding Wilms’ tumor protein 1 (WT1) administered alone o
Autor:
Osama E. Rahma, Darren W.T. Lim, Ravit Geva, Toshikiko Doi, A. Xyrafas, Philippe L. Bedard, Jennifer Marie Mataraza, Alexander M. Lesokhin, Javier Otero, Tira Jing Ying Tan, Angad P Singh, Xinhui Chen, Jason J. Luke, Lisa Nardi, Sarina Anne Piha-Paul, Cinta Hierro
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Scientia
Journal for Immunotherapy of Cancer
Scientia
BackgroundGWN323 is an IgG1 monoclonal antibody (mAb) against the glucocorticoid-induced tumor necrosis factor receptor-related protein. This first-in-human, open-label phase I/Ib study aimed to investigate the safety and tolerability and to identify
Autor:
Gernot Schabbauer, Alona Agirre-Lizaso, Ana Landa, Pedro Rodrigues, Sylvia Knapp, Omar Sharif, Patricia Munoz-Garrido, Colm J O'Rourke, Mikel Azkargorta, Patricia Aspichueta, Jesper B. Andersen, Adelaida La Casta, Derek A. Mann, Marco Y W Zaki, Aitor Esparza-Baquer, Ekaterina Zhuravleva, Raul Jimenez-Agüero, Elizabeth Hijona, Fiona Oakley, Felix Elortza, Jesus M. Banales, Ibone Labiano, Luis Bujanda, Maria J. Perugorria, Andrea Vogel, Ioana Riaño
Publikováno v:
Addi: Archivo Digital para la Docencia y la Investigación
Universidad del País Vasco
Addi. Archivo Digital para la Docencia y la Investigación
instname
Esparza-Baquer, A, Labiano, I, Sharif, O, Agirre-Lizaso, A, Oakley, F, Rodrigues, P M, Zhuravleva, E, O'Rourke, C J, Hijona, E, Jimenez-Agüero, R, Riaño, I, Landa, A, La Casta, A, Zaki, M Y W, Munoz-Garrido, P, Azkargorta, M, Elortza, F, Vogel, A, Schabbauer, G, Aspichueta, P, Andersen, J B, Knapp, S, Mann, D A, Bujanda, L, Banales, J M & Perugorria, M J 2020, ' TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms ', Gut, vol. 70, no. 7 . https://doi.org/10.1136/gutjnl-2019-319227
Universidad del País Vasco
Addi. Archivo Digital para la Docencia y la Investigación
instname
Esparza-Baquer, A, Labiano, I, Sharif, O, Agirre-Lizaso, A, Oakley, F, Rodrigues, P M, Zhuravleva, E, O'Rourke, C J, Hijona, E, Jimenez-Agüero, R, Riaño, I, Landa, A, La Casta, A, Zaki, M Y W, Munoz-Garrido, P, Azkargorta, M, Elortza, F, Vogel, A, Schabbauer, G, Aspichueta, P, Andersen, J B, Knapp, S, Mann, D A, Bujanda, L, Banales, J M & Perugorria, M J 2020, ' TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms ', Gut, vol. 70, no. 7 . https://doi.org/10.1136/gutjnl-2019-319227
[EN] Objective Hepatocellular carcinoma (HCC) is a prevalent and aggressive cancer usually arising on a background of chronic liver injury involving inflammatory and hepatic regenerative processes. The triggering receptor expressed on myeloid cells 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5101dbc9d21276c380d697790fd43d3c
http://hdl.handle.net/10810/52822
http://hdl.handle.net/10810/52822
Autor:
David R. Minor, Mark R. Albertini, Gary I. Cohen, Ahmad A. Tarhini, Sandra J. Lee, John M. Kirkwood, Harriet M. Kluger, Howard Streicher, Lawrence E. Flaherty, Henry B. Koon, Carrie B. Lee, Ni Kang, Kari Kendra, Jeffrey A. Sosman, Laura F. Hutchins, Zeynep Eroglu, Teresa M. Petrella, F. Stephen Hodi, Omid Hamid, Donald P. Lawrence, Vernon K. Sondak
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
BackgroundThe impact of immune-related adverse events (irAEs) occurring from adjuvant use of immunotherapy and of their management on relapse-free survival (RFS) and overall survival (OS) outcomes is currently not well understood.Patients and methods
Autor:
Sin-Ho Jung, Maria Angelica Selim, April K.S. Salama, Norma E. Farrow, Andrea Kelly, Darell D. Bigner, Georgia M. Beasley, Karenia Landa, Smita K. Nair, Matthias Gromeier, Carol Ann Wiggs
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 4 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundWhile programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) antagonists have improved the prognosis for many patients with melanoma, around 60% fail therapy. PVSRIPO is a non-neurovirulent rhinovirus:poliovirus chimer
Autor:
Robert S. Svatek, Zhen Ju Shu, Ryan Reyes, Jonathan Gelfond, Chethan Ramamurthy, Joshua J. Meeks, Tyler J. Curiel, Martin A. Javors, Ryan Dennett, David J. McConkey, Niannian Ji, Neelam Mukherjee
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundAlthough intravesical BCG is the standard treatment of high-grade non-muscle invasive bladder cancer (NMIBC), response rates remain unsatisfactory. In preclinical models, rapamycin enhances BCG vaccine efficacy against tuberculosis and the
Autor:
Yukio Kageyama, Minato Yokoyama, Soichiro Yoshida, Kazutaka Saito, Junichiro Ishioka, Yoh Matsuoka, Shohei Fukuda, Yasuhisa Fujii, Yosuke Yasuda, Toshiki Kijima
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
BackgroundThe dynamic change in C-reactive protein (CRP) levels, CRP kinetics, is a prognostic factor for metastatic renal cell carcinoma (mRCC) in the tyrosine kinase inhibitor era. We investigated the impact of early CRP kinetics on the efficacy of
Autor:
Ala Abudayyeh, Cassian Yee, Nizar M. Tannir, Maria E. Suarez-Almazor, Shana Machado, Biruh Workeneh, Sheldon Chen, Amanda Tchakarov, Umut Selamet, Lillian W. Gaber, Huifang Lu, William F Glass, Amit Lahoti, Omar Mamlouk, Jamie S. Lin, Noha Abdel-Wahab, Maen Abdelrahim, Jean Tayar, Adi Diab
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Rationale & Objective The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these age